Fundraising Fox

Foghorn Therapeutics

NASDAQ: FHTX

Incorporated in Delaware · 3 known investors

Find your way into Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.

Founders & leadership

AGAdrian Gottschalk
Adrian GottschalkPresident and Chief Executive Officer

Investors · 3

Flagship PioneeringCambridge · $500K – $10M
Biotechnology Value Fundreported · 2 sourcesSan Francisco
Deerfield Management Companyreported · 2 sourcesNew York

Funding

SEC filings, press & company announcements

$42M disclosed across 1 of 3 rounds · 2020–2026

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events
$451.1Mvaluation at IPOOct 2020 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Foghorn Therapeutics (NASDAQ: FHTX) trims expenses, raises $50M in Q1 2026stocktitan.net · May 2026Foghorn Therapeutics Raises $50M in Equity Financing | Precision Medicine Onlineprecisionmedicineonline.com · Jan 2026Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026globenewswire.com · Jan 2026Flagship Pioneering funds acquire over $20 million in Foghorn Therapeutics warrants By Investing.cominvesting.com · May 2024Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipelineglobenewswire.com · May 2024Foghorn Therapeutics raises $120 million in IPOstatnews.com · Oct 2020

Frequently asked questions

What does Foghorn Therapeutics do?
Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.
Who are Foghorn Therapeutics's investors?
Foghorn Therapeutics's investors include Flagship Pioneering, Biotechnology Value Fund, Deerfield Management Company.
How much funding has Foghorn Therapeutics raised?
Foghorn Therapeutics has disclosed $42M raised across 1 of its 3 known rounds.